Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2071031 | 0.92 | MEN1 (0.57) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL4432071 | 0.91 | KMT2A (0.65) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL29145305 | 0.90 | MTNR1A (0.62) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL1566774 | 0.87 | MEN1 (0.64) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL404391 | 0.87 | MEN1 (0.69) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL6565730 | 0.87 | KMT2A (0.56) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL5999001 | 0.85 | NQO2 (0.62) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL5014444 | 0.85 | MEN1 (0.62) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL1386334 | 0.85 | MEN1 (0.62) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL1386337 | 0.85 | MTNR1A (0.76) | MEN1MAPTKMT2AMTNR1ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029159-A | Preparation scheme of benzimidazole compound | 拉夸里亚创药株式会社 | 2026-05-12 | — | — | CN | claimed |
| WO-2025095097-A1 | Process for producing benzimidazole compound | RAQUALIA PHARMA INC. (JP) | 2025-05-08 | — | — | WO | claimed |
| CN-118852079-A | Method for synthesizing tergolian intermediate 5, 7-difluoro chroman-4-ketone | 浙江中科创越药业有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-122029159-A | Preparation scheme of benzimidazole compound | 拉夸里亚创药株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260028331-A1 | Methods And Intermediates for Preparing 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt | PFIZER INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4673436-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| EP-4558491-A1 | METHODS AND INTERMEDIATES FOR PREPARING 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID, 1,3-DIHYDROXY-2-(HYDROXYMETHYL)PROPAN-2-AMINE SALT | Pfizer Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025095097-A1 | Process for producing benzimidazole compound | RAQUALIA PHARMA INC. (JP) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024179948-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024018395-A1 | METHODS AND INTERMEDIATES FOR PREPARING 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID, 1,3-DIHYDROXY-2-(HYDROXYMETHYL)PROPAN-2-AMINE SALT | PFIZER INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024018395-A1 | METHODS AND INTERMEDIATES FOR PREPARING 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID, 1,3-DIHYDROXY-2-(HYDROXYMETHYL)PROPAN-2-AMINE SALT | PFIZER INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023154905-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023001298-A1 | PREPARATION METHOD FOR HEPATITIS B VIRUS NUCLEOCAPSID INHIBITOR | 上海挚盟医药科技有限公司 | 2023-01-26 | — | — | WO | disclosed |
| CN-111233748-B | Synthesis of tirofiban hydrochloride | 江苏慧聚药业股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3921316-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163193-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | MEN1 4063/4885MAPT 520/4885KMT2A 1148/4885 |
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | PKN3, PKMYT1, IP6K3 | MEN1 1807/4885MAPT 2795/4885KMT2A 557/4885 |
| US-20260028331-A1 | Methods And Intermediates for Preparing 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt | ADH1C, TET2, ADH1A | MEN1 1573/4885MAPT 2902/4885KMT2A 388/4885 |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | ENGASE, UGGT1, MGAT3 | MEN1 4510/4885MAPT 4269/4885KMT2A 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.